The article “Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study” by de Groot et al1 was published in Journal of Clinical Oncology. We commend the authors for investigating correlations between gene expression and clinical outcome and believe that their findings may provide important clues for maximizing the efficacy of antiangiogenic therapies.
